Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Fatal spontaneous Clostridium septicum gas gangrene: a possible association with iatrogenic gastric acid suppression.

Wu YE, Baras A, Cornish T, Riedel S, Burton EC.

Arch Pathol Lab Med. 2014 Jun;138(6):837-41. doi: 10.5858/arpa.2013-0104-CR.

PMID:
24878026
[PubMed - indexed for MEDLINE]
2.

The relationship between proton pump inhibitor adherence and fracture risk in the elderly.

Ding J, Heller DA, Ahern FM, Brown TV.

Calcif Tissue Int. 2014 Jun;94(6):597-607. doi: 10.1007/s00223-014-9855-6. Epub 2014 Apr 6.

PMID:
24706060
[PubMed - in process]
3.

Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.

Cea Soriano L, Ruigómez A, Johansson S, García Rodríguez LA.

Pharmacotherapy. 2014 Jun;34(6):570-81. doi: 10.1002/phar.1410. Epub 2014 Mar 13.

PMID:
24634193
[PubMed - in process]
4.

Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.

Moayyedi P, Yuan Y, Leontiadis G; CAG Clinical Affairs.

Can J Gastroenterol. 2013 Oct;27(10):593-5. No abstract available.

PMID:
24251323
[PubMed - indexed for MEDLINE]
5.

Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.

Abrahamsen B, Vestergaard P.

Bone. 2013 Nov;57(1):269-71. doi: 10.1016/j.bone.2013.08.013. Epub 2013 Aug 22.

PMID:
23973557
[PubMed - indexed for MEDLINE]
6.

Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.

Prieto-Alhambra D, Pagès-Castellà A, Wallace G, Javaid MK, Judge A, Nogués X, Arden NK, Cooper C, Diez-Perez A.

J Bone Miner Res. 2014 Jan;29(1):268-74. doi: 10.1002/jbmr.2011.

PMID:
23761350
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.

Lee J, Youn K, Choi NK, Lee JH, Kang D, Song HJ, Park BJ.

J Gastroenterol. 2013 Sep;48(9):1016-22. doi: 10.1007/s00535-012-0722-9. Epub 2013 Jan 11.

PMID:
23307040
[PubMed - indexed for MEDLINE]
8.

Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.

Reyes C, Formiga F, Coderch M, Hoyo J, Ferriz G, Casanovas J, Monteserín R, Brotons C, Rojas M, Moral I.

Bone. 2013 Feb;52(2):557-61. doi: 10.1016/j.bone.2012.09.028. Epub 2012 Sep 27.

PMID:
23023097
[PubMed - indexed for MEDLINE]
9.

Side effects of proton pump inhibitors.

[No authors listed]

Am Fam Physician. 2012 Jul 1;86(1):1. No abstract available.

PMID:
22962918
[PubMed - indexed for MEDLINE]
Free Article
10.

Reducing adverse effects of proton pump inhibitors.

Ament PW, Dicola DB, James ME.

Am Fam Physician. 2012 Jul 1;86(1):66-70. Review.

PMID:
22962914
[PubMed - indexed for MEDLINE]
Free Article
11.

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.

Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD; CaMos Research Group.

Osteoporos Int. 2013 Apr;24(4):1161-8. doi: 10.1007/s00198-012-2112-9. Epub 2012 Aug 14.

PMID:
22890365
[PubMed - indexed for MEDLINE]
12.

The association between proton pump inhibitor use and hip fracture cannot be explained by differences in dietary and lifestyle choices.

Targownik LE.

Evid Based Med. 2013 Feb;18(1):38-9. doi: 10.1136/ebmed-2012-100650. Epub 2012 Jul 10. No abstract available.

PMID:
22782918
[PubMed - indexed for MEDLINE]
13.

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W; CaMos Research Group.

Am J Gastroenterol. 2012 Sep;107(9):1361-9. doi: 10.1038/ajg.2012.200. Epub 2012 Jul 10. Erratum in: Am J Gastroenterol. 2013 Jan;108(1):157.

PMID:
22777336
[PubMed - indexed for MEDLINE]
14.

Will heartburn break your leg?

Stevenson JC.

Maturitas. 2012 Jun;72(2):97-8. doi: 10.1016/j.maturitas.2012.03.005. Epub 2012 Apr 18. No abstract available.

PMID:
22516279
[PubMed - indexed for MEDLINE]
15.

Incidence rates.

Sedgwick P.

BMJ. 2012 Mar 7;344:e1589. doi: 10.1136/bmj.e1589. No abstract available.

PMID:
22399704
[PubMed - indexed for MEDLINE]
16.

Fracture risk and bone mineral density reduction associated with proton pump inhibitors.

Lau YT, Ahmed NN.

Pharmacotherapy. 2012 Jan;32(1):67-79. doi: 10.1002/PHAR.1007. Review.

PMID:
22392829
[PubMed - indexed for MEDLINE]
17.

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study.

Khalili H, Huang ES, Jacobson BC, Camargo CA Jr, Feskanich D, Chan AT.

BMJ. 2012 Jan 30;344:e372. doi: 10.1136/bmj.e372.

PMID:
22294756
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

[Atypical subtrochanteric fractures after long-term bisphosphonate therapy].

Czerwiński E.

Endokrynol Pol. 2011;62 Suppl 2:42-5. Review. Polish.

PMID:
22125022
[PubMed - indexed for MEDLINE]
19.

Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy.

Hershcovici T, Fass R.

Drugs. 2011 Dec 24;71(18):2381-9. doi: 10.2165/11597300-000000000-00000.

PMID:
22117130
[PubMed - indexed for MEDLINE]
20.

ACP Journal Club. Proton-pump inhibitors were associated with reduced effectiveness of alendronate for preventing hip fractures.

Ito K.

Ann Intern Med. 2011 Oct 18;155(8):JC4-13. doi: 10.7326/0003-4819-155-8-201110180-02013. No abstract available.

PMID:
22007072
[PubMed]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk